Format

Send to

Choose Destination
Urol Oncol. 2015 Jun;33(6):269. doi: 10.1016/j.urolonc.2015.01.026. Epub 2015 Mar 26.

A window into new drug development for urologic oncology. Part II: Bench-to-bedside research improves survival in urologic cancer, and the discovery of better biomarkers can help predict patient response, toxicity, and resistance to therapy.

Author information

1
Astellas Global Medical Affairs, Northbrook, IL; Department of Urology, Loyola University School of Medicine, Maywood, IL. Electronic address: gabriel.haas@astellas.com.
2
Genitourinary Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY; Weill Cornell Medical College, New York, NY.
PMID:
25817318
DOI:
10.1016/j.urolonc.2015.01.026
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center